Repligen to Acquire BioLife Solutions for $1.5B in Cash and Stock
BLFS sits 74% above its 52-week low of $17.86 on elevated volume (11× avg).
Summary
Repligen Corporation will acquire BioLife Solutions in a $1.5 billion cash-and-stock deal, paying $31.00 per share—a 24% premium. The merger combines complementary cell therapy tools and is expected to close in Q4 2026.
Key Events · M&A and Partnerships · BLFS
-
Definitive Merger Agreement Signed
Repligen will acquire all outstanding BioLife shares for $11.25 cash and 0.1442 Repligen shares per BioLife share, implying a total value of $31.00 per share and a $1.5 billion enterprise value.
-
Premium and Deal Structure
The offer represents a 24% premium to BioLife's 90-day VWAP. Consideration is 36% cash and 64% stock, with a fixed exchange ratio of 0.1442 Repligen shares per BioLife share.
-
Expected Synergies and Accretion
Repligen expects at least $20 million in year-one synergies from eliminating public-company costs and operational efficiencies, with EPS accretion of at least $0.05 in year one and $0.25 in year two.
-
Preliminary Q2 2026 Revenue
BioLife reported preliminary Q2 revenue of $28.5 million, a 21% increase year-over-year. Repligen reported preliminary Q2 revenue growth of approximately 12% as reported.
Analysis · BLFS · Industrial Applications And Services
A definitive agreement has been reached for Repligen Corporation to acquire BioLife Solutions at $31.00 per share—$11.25 in cash and 0.1442 shares of Repligen common stock—valuing the company at approximately $1.5 billion. The offer represents a 24% premium to BioLife's 90-day VWAP and is expected to close in Q4 2026, subject to shareholder and regulatory approvals. By combining BioLife's market-leading biopreservation media franchise with Repligen's broader bioprocessing portfolio, the merger targets the fast-growing cell therapy market. Repligen expects at least $20 million in year-one synergies and EPS accretion of at least $0.05 in year one, rising to $0.25 in year two. BioLife also reported preliminary Q2 revenue of $28.5 million, up 21% year-over-year. The agreement includes a $59 million termination fee payable by BioLife under certain circumstances. This is a thesis-altering event that will fundamentally change BioLife's ownership and strategic direction.
At the time of this filing, BLFS was trading at $31.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $17.86 to $31.49. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.